Evaluation of drug-drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling

• Κύριοι συγγραφείς: Tao Ji (Συγγραφέας), Xuejun Chen (Συγγραφέας), Swamy Yeleswaram (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Wiley, 2022-07-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Abstract Pemigatinib is a potent inhibitor of fibroblast growth factor receptor being developed for oncology indications. It is primarily metabolized by cytochrome P450 (CYP) 3A4, and the ratio of estimated concentration over concentration required for 50% inhibition ratio for pemigatinib as an inhi...